BioTuesdays

Tag - IMTX

SVB Leerink starts Immatics at OP; PT $17

SVB Leerink initiated coverage of Immatics (NASDAQ:IMTX) with an “outperform” rating and $17 price target. The stock closed at $10.57 on July 24. Immatics is developing T-cell receptor (TCR)-based immunotherapies and...